TY - JOUR
T1 - National heart, lung, and blood institute working group on emergency department management of acute heart failure
T2 - Research challenges and opportunities
AU - Peacock, W. Frank
AU - Braunwald, Eugene
AU - Abraham, William
AU - Albert, Nancy
AU - Burnett, John
AU - Christenson, Rob
AU - Collins, Sean
AU - Diercks, Deborah
AU - Fonarow, Greg
AU - Hollander, Judd
AU - Kellerman, Art
AU - Gheorghiade, Mihai
AU - Kirk, Doug
AU - Levy, Phil
AU - Maisel, Alan
AU - Massie, Barry M.
AU - O'Connor, Christopher
AU - Pang, Peter
AU - Shah, Monica
AU - Sopko, George
AU - Stevenson, Lynne
AU - Storrow, Alan
AU - Teerlink, John
N1 - Funding Information:
The meeting that this manuscript was derived from was completely and solely supported by the National Heart, Lung, and Blood Institute . For full author disclosures, please see the end of this paper. Jay Cohn, MD, served as Guest Editor for this paper.
Funding Information:
Dr. Peacock has received research support from Abbott , Beckman-Coulter , Biosite , Brahms , Heartscape , EKR , and The Medicines Co. ; has received honoraria from Abbott, Beckman-Coulter, Biosite, EKR, and The Medicines Co.; and owns stock in Vital Sensors. Dr. Braunwald has received research support from Merck and Co., Inc. , Novartis , and Roche Diagnostics Corp. , and honoraria from Merck and Co. Dr. Abraham has received research support from Medtronic, Inc. , Paracor, Inc. , and St. Jude Medical , and honoraria from Medtronic, Inc., Respironics, St. Jude Medical, ARCA BioPharm, BioEnergy, Biotronik, Capricor, Cardiac Concepts, CardioKine, CardioKinetix, Inc., CardioMEMS, Edwards Lifesciences, and Paracor Inc. Dr. Albert has received honoraria from GlaxoSmithKline, Medtronic, Merck, and Impedance Cardiology Systems, Inc. Dr. Burnett has received research support from Bayer , Merck , Nile Therapeutics , BioRad , Trevena , and Anexon ; honoraria from Nile Therapeutics, Otsuka, and Anexon; and royalties from Nile Therapeutics and Anexon. Dr. Christenson has received research support from Siemens Healthcare Diagnostics , Roche Diagnostics , BG Medicine , and Critical Care Diagnostics , and honoraria from Siemens. Dr. Collins has received research support from Biosignetics , Inovise Medical, Inc. , Abbott Point-of-Care , Corthera , and Brahms , and honoraria from Abbott Point-of-Care, PDL BioPharma, Astellas, Otsuka Pharmaceuticals, The Medicines Co., and Corthera. Dr. Fonarow has received honoraria from Novartis, Medtronic, Scios, GlaxoSmithKline, Pfizer, and Merck. Dr. Gheorghiade has received honoraria from Abbott Labs, Astellas, Astra Zeneca, Bayer Schering Pharma AG, CorThera, Inc., Cytokinetics, Inc., DebioPharm S.A., Errekappa Terapeutici (Milan, Italy), GlaxoSmithKline, Ikaria, Johnson & Johnson, Medtronic, Merck, Novartis Pharma AG, Otsuka Pharmaceuticals, Palatin Technologies, Pericor Therapeutics, Protein Design Laboratories, Sanofi-Aventis, Sigma Tau, Solvay Pharmaceuticals, and Trevena Therapeutics. Dr. Hollander has received research support from Siemens Diagnostics , Brahms , Nanosphere , and Biosite/Inverness , and honoraria from Sanofi-Aventis and Bristol-Myers Squibb. Dr. Kirk has received honoraria from Sanofi-Aventis, Otsuka, and Biosite. Dr. Levy has received research support from GlaxoSmithKline , The Cleveland Clinic Foundation , Astellas Pharma US, Inc. , Solvay Pharmaceuticals , Corthera, Inc. , Nile Therapeutics, Inc. , Biosite, Inc. , Cardiodynamics, Inc. , and Inovise Medical , and honoraria from The Medicines Co. Dr. Maisel has received research support from Inverness , Brahms , Critical Diagnostics , Abbott , and Nanosphere , and honoraria from Inverness. Dr. Massie has received honoraria from Merck-Novacardia, Corthera, Cytokinetics, Novartis, Nile Therapeutics, and Boston Scientific Co. Dr. O'Connor has received research support from Johnson & Johnson , Merck , Forest , Medtronic , and Roche Diagnostics , and honoraria from Johnson & Johnson, Merck, Forest, Medtronic, and Roche Diagnostics. Dr. Pang has received research support from Merck and PDL BioPharma , and honoraria from Astellas, Bayer, EKR Therapeutics, Johnson & Johnson, The Medicines Co., Otsuka, Palatin Technologies, PDL BioPharma, Pericor Therapeutics, Solvay, BiogenIdec, Corthera, Ikaria, and Nile Therapeutics. Dr. Stevenson has received honoraria from Medtronics, Inc. Dr. Storrow has received research support from Biosignetics , PDL BioPharma , Abbott Diagnostics , and Meso Scale Discovery , and honoraria from Abbott Diagnostics, Ortho-Clinical Diagnostics, and Sanofi-Aventis. Dr. Teerlink has received research support and honoraria from Abbott/Orion , Actelion , Amgen , Astellas , AstraZeneca , BAS Medical/Corthera , Biogen Idec , Bristol-Myers Squibb , Cardio-Dynamics , Cardioxyl , CHF Solutions , CoGeneSys/Teva , Cytokinetics , Geron , GlaxoSmithKline , Medtronic , Momentum Research , National Institutes of Health , NovaCardia/Merck , Novartis , Protein Design Labs , Relypsa , Sanofi-Aventis , Scios/Johnson & Johnson , and Zealand Pharma .
PY - 2010/7/27
Y1 - 2010/7/27
N2 - This paper details the substance and recommendations arising from a meeting convened by the National Heart, Lung, and Blood Institute in August 2009, to assess the challenges and opportunities of emergency department management of acute heart failure syndrome (AHFS). The assembled faculty represented a large cross section of medical professionals spanning the medical management continuum of patients presenting with acute heart failure and included heart failure cardiologists, emergency physicians, laboratory medicine specialists, nurses, and bench scientists. Their recommendations include proposals regarding the design and conduct of emergency department-based clinical trials, suggestions regarding the development of improved methods for early detection and monitoring of AHFS, and potential needs for expanding translational and applied AHFS focused research and biotechnology. We anticipate that this review will serve as a starting point for future investigations across the spectrum of funding sources.
AB - This paper details the substance and recommendations arising from a meeting convened by the National Heart, Lung, and Blood Institute in August 2009, to assess the challenges and opportunities of emergency department management of acute heart failure syndrome (AHFS). The assembled faculty represented a large cross section of medical professionals spanning the medical management continuum of patients presenting with acute heart failure and included heart failure cardiologists, emergency physicians, laboratory medicine specialists, nurses, and bench scientists. Their recommendations include proposals regarding the design and conduct of emergency department-based clinical trials, suggestions regarding the development of improved methods for early detection and monitoring of AHFS, and potential needs for expanding translational and applied AHFS focused research and biotechnology. We anticipate that this review will serve as a starting point for future investigations across the spectrum of funding sources.
KW - emergency medicine
KW - heart failure
KW - research
UR - http://www.scopus.com/inward/record.url?scp=77955293320&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77955293320&partnerID=8YFLogxK
U2 - 10.1016/j.jacc.2010.03.051
DO - 10.1016/j.jacc.2010.03.051
M3 - Review article
C2 - 20650354
AN - SCOPUS:77955293320
SN - 0735-1097
VL - 56
SP - 343
EP - 351
JO - Journal of the American College of Cardiology
JF - Journal of the American College of Cardiology
IS - 5
ER -